Compounded tirzepatide dosing math: accurate basics, real safety gaps

What did @risinghealthreport actually say?

The creator held up a compounded tirzepatide vial from Empower Pharmacy and walked through a specific label format: "eight slash two milligrams per milliliter." Their interpretation was that this means 8mg of tirzepatide per mL and 2mg of niacinamide per mL, not a fraction of 8 over 2. They also said concentrations vary by provider and compounding pharmacy, and they closed with a sensible disclaimer to check with your provider before dosing.

This is a practical, math-focused video aimed at patients who are confused by vial labels, which is a genuinely common problem. Compounded GLP-1 vials do not come with the kind of standardized patient labeling you get from a retail pharmacy, so the confusion the creator is addressing is real and documented in clinical settings.

Does the science back this up?

Yes, on the chemistry. The slash notation on compounded vials is a recognized shorthand for multi-ingredient formulations, not a division symbol. The creator's read of "8/2 mg/mL" as two separate concentrations in the same solution is correct.

Niacinamide is sometimes added to compounded tirzepatide by certain pharmacies. The rationale cited by compounders is that niacinamide may improve injection site tolerability, though the evidence for this specific benefit in GLP-1 formulations is thin. There are no published randomized trials confirming that niacinamide reduces injection site reactions when compounded with tirzepatide specifically. The FDA has not evaluated or approved this combination. Patients should understand that multi-ingredient compounded formulations introduce variables that brand-name products do not have, and that is not a minor footnote.

The broader point that concentration varies by compounding pharmacy is well-supported. A 2023 analysis in JAMA highlighted significant variability in compounded semaglutide products, and similar concerns apply to tirzepatide compounding (Sinha et al., 2023, JAMA).

What did they get wrong (or right)?

They got the core math right. The label interpretation is accurate, and the advice to "refer back to your provider" before deciding how much to inject is exactly what patients should hear. Credit where it is due.

What is missing is more significant than what is wrong. The creator does not mention that compounded tirzepatide is not FDA-approved, that it is not therapeutically equivalent to Zepbound or Mounjaro, and that the addition of niacinamide is not an FDA-evaluated combination. The FDA issued warnings in 2024 specifically about compounded tirzepatide products, noting that compounded drugs lack the safety and efficacy review of approved products. A video teaching people how to read compounded vial labels without mentioning any of this context is incomplete at best.

There is also no mention of the risk of dosing errors, which are documented and serious. A 2024 FDA MedWatch summary flagged multiple adverse events tied to incorrect dosing of compounded GLP-1 products, some involving concentration misreads of exactly the type this video is trying to correct.

What should you actually know?

If you have a compounded tirzepatide vial, reading the label correctly does matter, and this video helps with that specific task. But knowing what the numbers mean is only one part of safe use.

• Compounded tirzepatide is not the same as Zepbound or Mounjaro. It has not undergone the same manufacturing review, and potency can vary between lots and pharmacies.
• The niacinamide addition is not standardized across compounders. If your vial contains it, ask your prescriber why it is included and what the expected effect is.
• The FDA placed compounded tirzepatide on its "difficult to compound" list in 2024, which creates legal and supply complications independent of safety questions.
• Dosing errors with compounded GLP-1s have sent people to emergency departments. Always confirm your draw volume with your prescribing provider, not a TikTok video, including this one.
• If your vial label is unclear, contact the compounding pharmacy directly. They are required to provide a certificate of analysis and should be able to clarify concentration labeling.